1. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Am J Clin Nutr. 2025;122:344–367.

2. Fitch A, Gigliotti L, Bays HE. Application of nutrition interventions with GLP-1 based therapies. Obesity Pillars. 2025;16:100205.

3. Sibal R, Balamurugan G, Langley J, et al. Macronutrient, micronutrient supplementation and monitoring for patients on GLP-1 agonists. Nutrients. 2025;17:3659.

4. European Parliament and Council. Regulation (EC) No 1924/2006 on nutrition and health claims made on foods. Off J Eur Union. 2006;L404:9–25.

5. European Commission. Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health. Off J Eur Union. 2012;L136:1–40.

6. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27.

7. Bear, D. E., Langan, A., Dimidi, E., Wandrag, L., Harridge, S. D. R., Hart, N., Connolly, B., & Whelan, K. (2019). β-Hydroxy-β-methylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice: A systematic review and meta-analysis. American Journal of Clinical Nutrition, 109(4), 1119–1132. https://doi.org/10.1093/ajcn/nqy373

8. Orsso, C. E., Caretero, A., Poltronieri, T. S., Arends, J., de van der Schueren, M. A., Kiss, N., Laviano, A., & Prado, C. M. (2024). Effects of high-protein supplementation during cancer therapy: a systematic review and meta-analysis. American Journal of Clinical Nutrition, 120(6), 1311–1324. https://doi.org/10.1016/j.ajcnut.2024.08.016